EVOLUTION OF Aβ42 AND Aβ40 LEVELS AND Aβ42/Aβ40 RATIO IN PLASMA DURING PROGRESSION OF ALZHEIMER'S DISEASE: A MULTICENTER ASSESSMENT

被引：44

作者：

Blennow, K. ^{[2
]}

De Meyer, G. ^{[1
]}

Hansson, O. ^{[3
]}

Minthon, L. ^{[3
]}

Wallin, A.

Zetterberg, H. ^{[2
]}

Lewczuk, P.

Vanderstichele, H. ^{[1
]}

Vanmechelen, E. ^{[1
]}

Kornhuber, J. ^{[6
]}

Wiltfang, J. ^{[5
]}

机构：

[1] Innogenetics, Ghent, Belgium

[2] Univ Gothenburg, Sahlgrenska Univ Hosp, Gothenburg, Sweden

[3] Lund Univ, Clin Memory Res Unit, Dept Clin Sci, Dept Psychiat, Malmo, Sweden

[4] Campus Benjamin Franklin, Charite, KND Study Grp, Berlin, Germany

[5] Univ Duisburg Essen, Kliniken Inst, Essen, Germany

[6] Univ Hosp Erlangen, Dept Psychiat, Erlangen, Germany

来源：

JOURNAL OF NUTRITION HEALTH & AGING | 2009年 / 13卷 / 03期

关键词：

MILD COGNITIVE IMPAIRMENT; AMYLOID-BETA CONCENTRATIONS; CSF BIOMARKERS; A-BETA; CEREBROSPINAL-FLUID; DEMENTIA; RISK; ASSOCIATION; STABILITY; PROTEIN;

D O I：

10.1007/s12603-009-0059-0

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Objective: To better understand the seemingly contradictory plasma beta-amyloid (A beta) results in Alzheimer's disease (AD) patients by using a newly developed plasma A beta assay, the INNO-BIA plasma A beta forms, in a multicenter study. Methods: A combined retrospective analysis of plasma A beta isoforms on mild cognitive impairment (MCI) from three large cross-sectional studies involving 643 samples from the participating German and Swedish centers. Results: Detection modules based on two different amino (N)-terminal specific A beta monoclonal antibodies demonstrated that A beta in plasma could be reliable quantified using a sandwich immunoassay technology with high precision, even for low A beta 42 plasma concentrations. A beta 40 and A beta 42 concentrations varied consistently with the ApoE genotype, while the A beta 42/A beta 40 ratio did not. Irrespective of the decrease of the A beta 42/A beta 40 ratio with age and MMSE, this parameter was strongly associated with AD, as defined in this study by elevated hyperphosphorylated (P-tau181P) levels in cerebrospinal fluid (CSF). Conclusion: A highly robust assay for repeatedly measuring A beta forms in plasma such as INNO-BIA plasma A beta forms might be a useful tool in a future risk assessment of AD.

引用

页码：205 / 208

页数：4

共 24 条

[1] The influence of diagnosis, intra- and inter-person variability on serum and plasma Aβ levels [J].